Est. 2001·3,000+ placements · six offices · four regions

Company signals

Versapay

1 signal in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: Backdrop: a 100.1 (Neutral) Talent Market Index (down 1.1 on the month) with Americas activity easing (-1.8pts).

Versapay: 1 signal in the last 90 days.

Signals at Versapay

Executive hires, departures and board changes at Versapay

Every leadership-change and senior-hiring signal observed at Versapay, newest first, each dated and linked to the source record.

Versapay signals in the last 90 days

1 public signal observed since 23 May 2026, by type.

More signals across Americas

Leadership Change · Americas

Sonic Healthcare

Sonic Healthcare appointed new boss Jim Newcombe, who has launched a review of the company's underperforming US operations.

Leadership Change · Americas

AXA XL

Kerry Vitolano appointed as Head of East US Risk Management and Head of US Risk Management at AXA XL, reporting to Matthew Stitham (Chief Underwriting Officer, Casualty in the Americas)

Leadership Change · Americas

Array

Array promoted Chad Hoffman to President and Lindsay Duprey to Chief Operating Officer in executive restructuring aimed at strengthening continuity and operational streamlining.

Leadership Change · Americas

BairesDev

Darren Shimkus appointed CEO effective immediately; co-founder Nacho De Marco transitions to Chairman. Shimkus previously joined as advisor in December 2024, moved to full-time role June 2025, and was President following BairesDev's acquisition of Modal in 2025.

Leadership Change · Americas

Ava Labs

Ava Labs appointed Charley Cooper as president and promoted Lydia Chiu to permanent CFO

Leadership Change · Americas

Peptilogics

Peptilogics appointed Tim Czartoski, former DePuy Synthes U.S. President and most recently president of U.S. Surgical and Global R&D at Enovis, to its board of directors. Czartoski brings 22 years of orthopedic device experience and expertise in surgical workflows and product commercialization as Peptilogics advances zaloganan (PLG0206) through Phase 2/3 trials for prosthetic joint infections.

Where Versapay's market lands in our work

Weekly briefing

Track companies like Versapay — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗